Precision BioSciences, Inc. (DTIL)
Largest Insider Buys in Sector
DTIL Stock Price History Chart
DTIL Stock Performance
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute …
Insider Activity of Precision BioSciences, Inc.
Over the last 12 months, insiders at Precision BioSciences, Inc. have bought $0 and sold $131,927 worth of Precision BioSciences, Inc. stock.
On average, over the past 5 years, insiders at Precision BioSciences, Inc. have bought $94,066 and sold $1.97M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 90,000 shares for transaction amount of $43,200 was made by Kelly John Alexander (Chief Financial Officer) on 2023‑08‑18.
List of Insider Buy and Sell Transactions, Precision BioSciences, Inc.
| 2024-11-04 | Sale | President and CEO | 3,012 0.0412% | $8.19 | $24,668 | +1.03% | ||
| 2024-11-04 | Sale | General Counsel and Secretary | 588 0.008% | $8.19 | $4,816 | +1.03% | ||
| 2024-06-10 | Sale | Chief Research Officer | 50 0.0007% | $11.79 | $590 | -22.38% | ||
| 2024-06-10 | Sale | General Counsel and Secretary | 93 0.0013% | $11.79 | $1,096 | -22.38% | ||
| 2024-05-02 | Sale | Chief Research Officer | 154 0.0021% | $10.32 | $1,589 | -9.87% | ||
| 2024-05-02 | Sale | President and CEO | 1,526 0.021% | $10.32 | $15,748 | -9.87% | ||
| 2024-05-02 | Sale | General Counsel and Secretary | 272 0.0037% | $10.32 | $2,807 | -9.87% | ||
| 2024-05-02 | Sale | Chief Medical Officer | 290 0.004% | $10.32 | $2,993 | -9.87% | ||
| 2024-05-01 | Sale | General Counsel and Secretary | 918 – | $0 | $0 | -6.49% | ||
| 2024-04-30 | Sale | Chief Medical Officer | 238 0.0033% | $10.03 | $2,386 | -5.66% | ||
| 2024-01-23 | Sale | Chief Research Officer | 28,000 0.0231% | $0.37 | $10,360 | +2678.53% | ||
| 2024-01-22 | Sale | President and CEO | 137,390 0.1111% | $0.36 | $49,460 | +2670.74% | ||
| 2024-01-22 | Sale | General Counsel and Secretary | 21,287 0.0172% | $0.36 | $7,663 | +2670.74% | ||
| 2024-01-22 | Sale | Chief Medical Officer | 21,526 0.0174% | $0.36 | $7,749 | +2670.74% | ||
| 2023-11-03 | Sale | President and CEO | 125,025 0.1021% | $0.40 | $50,010 | +2183.83% | ||
| 2023-11-03 | Sale | General Counsel and Secretary | 16,023 0.0131% | $0.40 | $6,409 | +2183.83% | ||
| 2023-08-18 | Chief Financial Officer | 90,000 0.0791% | $0.48 | $43,200 | +1.94% | |||
| 2023-06-08 | Sale | General Counsel and Secretary | 13,361 0.0119% | $0.75 | $10,021 | -30.52% | ||
| 2023-04-27 | Sale | Chief Medical Officer | 7,771 0.0067% | $0.79 | $6,139 | -35.85% | ||
| 2023-03-22 | Sale | President and CEO | 46,999 0.0438% | $0.82 | $38,539 | -33.50% |
Insider Historical Profitability
| FMR LLC | 3738248 48.7318% | $6.43 | 1 | 0 | <0.0001% | |
| Kelly John Alexander | Chief Financial Officer | 383340 4.9972% | $6.43 | 6 | 0 | <0.0001% |
| YAO TONY DUNG LING | director | 158003 2.0597% | $6.43 | 1 | 0 | <0.0001% |
| venBio Global Strategic Fund, L.P. | director | 50000 0.6518% | $6.43 | 1 | 0 | <0.0001% |
| Heery Christopher | Chief Medical Officer | 2485 0.0324% | $6.43 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Tang Capital Management, LLC | $7.99M | 8.51 | 589,569 | -82.66% | -$38.11M | 0.03 | |
| Janus Henderson | $7.74M | 8.27 | 573,052 | New | +$7.74M | <0.01 | |
| Perceptive Advisors | $6.52M | 6.94 | 480,483 | New | +$6.52M | <0.01 | |
| Spyglass Capital Management LLC | $5.23M | 5.57 | 385,440 | New | +$5.23M | 3.92 | |
| The Vanguard Group | $3.54M | 3.77 | 260,831 | -94.51% | -$60.94M | <0.0001 |